Tchernev Georgi, Temelkova Ivanka
Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, General Skobelev Nr 79, Sofia, Bulgaria.
Onkoderma, Policlinic for Dermatology and Dermatologic Surgery, General Skobelev 26, Sofia, Bulgaria.
Open Access Maced J Med Sci. 2018 Jul 12;6(7):1263-1266. doi: 10.3889/oamjms.2018.288. eCollection 2018 Jul 20.
Innovations in medicine are often due to the simplicity of a certain activity, interaction, even counteraction, or a mistake leading to a subsequent final optimal outcome. Innovations could also be due to conclusions based on targeted clinical or sporadic, as well as completely random observations. The genius of an approach or statement is often based on the "iron logic", which in turn is based on irrefutable data or facts. These are often observations or results from actions that happen right before our eyes and provide advantages or prerequisites for the better future development of things (in this case, disease) concerning certain groups of people (in these case-patients). When the clinical results achieved following an inevitable introduction of certain methods or innovations speak eloquently of a number of advantages in terms of 1) spearing effect on the patients, 2) better control or prevention of possible local and/or distant metastatic spread 3) better financial balance for the health institutions and patients, …, then even the "Gods of certain latitudes" should be silenced. We at this moment present a completely new method or approach for surgical treatment of cutaneous melanoma that once again proves the effectiveness of one-step melanoma surgery, which was successfully first officialised in the world literature again by the Bulgarian Society of Dermatologic Surgery, (BULSDS). In some cases, this method does not even require the preoperative use of a high-frequency ultrasound for determining the tumour thickness.
In patients with advanced stage of cutaneous melanoma, removal of a primary draining lymph node and/or locoregional lymph nodes is often performed simultaneously. However, it remains unclear why in patients with early-stage (or intermediate, with moderately thick melanomas) disease high-frequency ultrasound is not applied as a routine method of determination of tumour thickness? Meanwhile, re-excision is required following histopathological verification? Is it necessary to have 2 surgical interventions? The two surgical interventions are a burden for the patients and create prerequisites for contradicting opinions, statements, and subsequent results, which ultimately slows down the patient's staging and the introducing more precise treatments. Based on the logic (and further aided by the clinical picture and dermatoscopy), we decided to operate selected cases of patients with cutaneous melanomas with a field of surgical security of 1cm in all directions when clinical, and dermatoscopic data are indicative of melanoma in situ or thin melanomas (less than 1 cm). Optimal results were achieved, with one surgical intervention and subsequent rehospitalisation spared for the patient.
An answer to the question whether it is better not to follow the guidelines strictly (since, as a rule, they are generally recommended and somewhat misleading in certain circles of specialists, and as we have already found, also lead to unjustified logical secondary excisions), or update them at least annually when data for better tumor control is available (using a new method such as the one we mentioned above), should be searched for. This is a method not derived from AJCC/USA or other similar/equal or equivalent organisation's "recesses"! Acceptability of innovations depends to a large extent on the latitude or territory where they originated?! Something that should be changed! Or in other words, something that has already been changed! The End of Conformity, and the beginning of a New Era!
医学创新往往源于某种活动、相互作用、甚至反作用的简单性,或者一个导致后续最终最佳结果的错误。创新也可能源于基于有针对性的临床或零星以及完全随机观察得出的结论。一种方法或陈述的精妙之处通常基于“铁逻辑”,而这又基于无可辩驳的数据或事实。这些往往是我们眼前发生的行动的观察结果或成果,为涉及特定人群(在此指患者)的事物(在此指疾病)的更好未来发展提供优势或前提条件。当不可避免地引入某些方法或创新后所取得的临床结果雄辩地表明在以下方面具有诸多优势:1)对患者的穿刺效果;2)更好地控制或预防可能的局部和/或远处转移扩散;3)对卫生机构和患者更好的财务平衡等,那么即使是“某些地区的权威”也应保持沉默。此刻,我们展示一种全新的皮肤黑色素瘤手术治疗方法,再次证明了一步式黑色素瘤手术的有效性,该方法首次由保加利亚皮肤外科学会(BULSDS)成功正式发表于世界文献。在某些情况下,这种方法甚至不需要术前使用高频超声来确定肿瘤厚度。
在晚期皮肤黑色素瘤患者中,通常会同时切除初级引流淋巴结和/或局部区域淋巴结。然而,尚不清楚为何在早期(或中期,黑色素瘤厚度中等)疾病患者中,高频超声未被用作确定肿瘤厚度的常规方法?与此同时,在组织病理学验证后需要再次切除?是否需要进行两次手术干预?这两次手术干预对患者来说是一种负担,并为相互矛盾的观点、陈述及后续结果创造了前提条件,最终减缓了患者的分期并阻碍引入更精确的治疗。基于逻辑(并进一步借助临床症状和皮肤镜检查),当临床和皮肤镜数据表明为原位黑色素瘤或薄黑色素瘤(小于1厘米)时,我们决定对选定的皮肤黑色素瘤患者进行手术,手术安全范围为各方向1厘米。取得了最佳效果,避免了患者进行第二次手术干预及后续再次住院。
应该探寻这样一个问题的答案:是最好不要严格遵循指南(因为通常它们虽被普遍推荐,但在某些专家圈子中存在一定误导性,而且正如我们已经发现的,还会导致不合理的逻辑二次切除),还是在有更好的肿瘤控制数据可用时(例如使用我们上述提到的新方法)至少每年更新指南?这是一种并非源自美国癌症联合委员会(AJCC)或其他类似/同等组织的方法!创新的可接受性在很大程度上取决于其起源的地区或领域?!这是应该改变的!或者换句话说,这已经在改变!遵循常规的终结,新时代的开端!